Gopinath v. Somalogic, Inc.

CourtDistrict Court, S.D. California
DecidedAugust 21, 2023
Docket3:23-cv-01164
StatusUnknown

This text of Gopinath v. Somalogic, Inc. (Gopinath v. Somalogic, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gopinath v. Somalogic, Inc., (S.D. Cal. 2023).

Opinion

1 2 3 4 5 6 7 8 9 10 UNITED STATES DISTRICT COURT 11 SOUTHERN DISTRICT OF CALIFORNIA 12 13 ASHWIN GOPINATH, Case No.: 23-cv-1164-W-WVG

14 Plaintiff, ORDER GRANTING IN PART 15 v. AND DENYING IN PART SOMALOGIC, INC.’S MOTION 16 SOMALOGIC, INC., a Delaware TO DISMISS PLAINTIFF’S corporation; and DOES 1 through 20, 17 COMPLAINT AND STRIKE inclusive, PRAYER FOR EXEMPLARY 18 AND PUNITIVE DAMAGES Defendants. 19 [DOC. 7]

20 21 Pending before the Court is Defendant SomaLogic, Inc.’s Motion To Dismiss 22 Plaintiff’s Complaint and Strike Prayer for Exemplary and Punitive Damages (the 23 “Motion”) [Doc. 7]. 24 The Court decides the matter on the papers submitted and without oral argument. 25 See Civ. R. 7.1(d)(1). For the following reasons, the Court GRANTS IN PART and 26 DENIES IN PART SomaLogic’s Motion [Doc. 7]. 27 28 1 I. FACTUAL BACKGROUND 2 Plaintiff Dr. Gopinath, cofounded Palamedrix, Inc. (“Palamedrix”) and served as 3 Chief Technology Officer for the company. (Compl. [Doc. 12] ¶¶ 17, 19.) In 2021, the 4 Defendant in this case, SomaLogic, Inc. (“SomaLogic”), approached Palamedrix to 5 discuss a potential merger. (Id. ¶¶ 18, 22.) After about one year of negotiations, 6 SomaLogic and Palamedrix entered into a merger agreement on July 25, 2022 (“Merger 7 Agreement”). (Id. ¶ 25.) 8 Under the Merger Agreement, SomaLogic agreed to pay $35 million upon closing 9 of the merger, comprising $14 million cash (“Upfront Cash Consideration”) and $21 10 million in SomaLogic common stock (“Upfront Stock Consideration”). (Id. ¶ 26.) The 11 Upfront Stock Consideration was divided between Dr. Gopinath and Palamedrix’s other 12 Founders. (Id.) SomaLogic also agreed to pay up to an additional $17.5 million in 13 “Milestone Consideration” to the Founders if SomaLogic achieved certain revenue-based 14 milestones by 2027 and 2028. (Id. ¶ 33.) Under the Merger Agreement, a Founder is not 15 eligible to receive this additional consideration unless the Founder “remains a full-time 16 employee” with SomaLogic when the milestones are achieved. (Id. ¶ 34.) 17 In connection with the Merger Agreement, SomaLogic provided Dr. Gopinath with 18 a Founder Side Letter Agreement, dated July 25, 2022 (“Founder Side Letter”). (Id. ¶ 19 27.) Under the Founder Side Letter, Dr. Gopinath’s Upfront Stock Consideration was 20 “fully vested ‘subject to the risk of forfeiture[.]’” (Id. ¶¶ 27–29.) The Founder Side 21 Letter provides that Dr. Gopinath would automatically forfeit certain percentages of the 22 Upfront Stock Consideration if he left SomaLogic before the 12- month, 24-month, or 23 36-month anniversaries of the merger’s closing. (Id. ¶ 28.) But if Dr. Gopinath resigned 24 for “Good Reason” (or was terminated without “Cause”), then his Upfront Stock 25 Consideration would “no longer be subject to forfeiture.” (Id. ¶ 29.) The Merger 26 Agreement defines “Good Reason” to include “a material, adverse change in [a] 27 Founder’s title, authority, duties or responsibilities.” (Id. ¶ 30.) 28 1 SomaLogic’s merger with Palamedrix successfully closed on August 31, 2022. 2 (Id. ¶ 25.) After the merger, Dr. Gopinath joined SomaLogic as Senior Director, Assay 3 Development and reported to Dr. Shane Bowen. (Id. ¶ 35.) As required by the parties’ 4 agreements, SomaLogic paid Dr. Gopinath his portion of the Upfront Stock 5 Consideration upon closing, comprising millions of dollars in compensation. (Id. ¶¶ 26, 6 32.) 7 Issues between Dr. Gopinath and SomaLogic quickly piled up. Dr. Gopinath 8 alleges that “SomaLogic [] prevented former Palamedrix employees from continuing 9 their research and development” and “ma[de] it unnecessarily difficult for former 10 Palamedrix employees to buy even the most basic supplies for research.” (Id. ¶ 43.) He 11 further alleges that SomaLogic’s Vice President of Technology Development, Shane 12 Bowen, “harasses, demeans, and discriminates against SomaLogic’s female employees.” 13 (Id. ¶ 45.) In an interview with SomaLogic’s Senior Vice President of People & Culture, 14 Alison Roelke, Dr. Gopinath “confirmed that Mr. Bowen engaged in inappropriate 15 behavior.” (Id. ¶ 46.) 16 According to Dr. Gopinath, “SomaLogic’s bungling of the Palamedrix acquisition, 17 its mismanagement of former Palamedrix employees, and its promotion of Mr. Bowen 18 led most of Dr. Gopinath’s team from Palamedrix to quit.” (Id. ¶ 51.) This included four 19 of Dr. Gopinath’s six reports. (Id. ¶ 6.) Dr. Gopinath alleges that the “loss of former 20 Palamedrix employees substantially impaired Dr. Gopinath’s ability to execute his duties 21 and responsibilities and achieve the Milestones.” (Id. ¶ 54.) Furthermore, “SomaLogic 22 impeded Dr. Gopinath’s attempts to replace these former Palamedrix employees” and 23 “did not provide Dr. Gopinath with the budget to hire a complete and qualified team 24 needed to achieve the Milestones.” (Id. ¶ 55–56.) 25 Less than three months after the merger closed, in November 2022, Dr. Gopinath 26 “notified SomaLogic that he had Good Reason to resign.” (Id. ¶ 58.) “In response, Dr. 27 Gopinath was banned from SomaLogic’s offices.” (Id. ¶ 59.) A few months later, Dr. 28 Gopinath emailed SomaLogic’s Board of Directors to report that he had “faced 1 problematic behavior from [his] chain of command and HR[.]” (Id. ¶ 68.) Dr. Gopinath 2 “reported Mr. Bowen’s unethical and unlawful conduct to SomaLogic’s Board of 3 Directors” and expressed his concern that “there is a systemic problem with the 4 Somalogic culture and leadership.” (Id. ¶¶ 67, 71.) According to Dr. Gopinath, when he 5 tried to address these issues with SomaLogic leadership he “was immediately asked to 6 work remotely, given vague tasks with unclear instructions, and asked to create an IP 7 paper trail that could create issues for Somalogic, for which [he] would likely be blamed 8 later.” (Id. ¶ 70.) 9 In response to Dr. SomaLogic’s email, “SomaLogic revoked Dr. Gopinath’s access 10 to SomaLogic’s systems and his SomaLogic email account.” (Id. ¶ 73.) About a month 11 later, Dr. Gopinath “resigned” from his position at SomaLogic when he emailed notice of 12 “his resignation” to several SomaLogic executives. (Id. ¶ 75.) In that email, Dr. 13 Gopinath stated that his resignation was “effective immediately.” (Id.) Later that day, 14 SomaLogic sent him a “termination letter” that “purport[ed]” to “terminate[]” his 15 employment with SomaLogic “effective immediately.” (Id. ¶ 77.) 16 17 II. PROCEDURAL HISTORY 18 SomaLogic brought this motion on June 29, 2023. SomaLogic’s first argument in 19 the Motion was that the Complaint should be dismissed under the forum non conveniens 20 doctrine based on the Forum Selection Clause in the Employment Agreement between 21 the Parties. (Mot. at 6.) On July 27, 2023, while this motion was pending, SomaLogic 22 informed Dr. Gopinath that it was “withdrawing its forum non conveniens argument.” 23 (See Decl. of R. Taylor [Doc. 13-1] at 1.) In its Reply, SomaLogic withdrew the forum 24 non conveniens argument reflected in Section III.A of the Motion. (Reply [Doc. 15] at 2, 25 n. 1.) SomaLogic’s other arguments as to its motion to dismiss and motion to strike 26 remain. 27 28 1 III. MOTION TO DISMISS 2 A. Legal Standard 3 Federal Rule of Civil Procedure 12(b)(6) allows a defendant to file a motion to 4 dismiss for failing “to state a claim upon which relief can be granted.” Fed. R. Civ. P. 5 12(b)(6). A motion to dismiss under Rule 12(b)(6) tests the complaint’s sufficiency. See 6 N. Star Int’l v. Ariz. Corp. Comm’n., 720 F. 2d 578, 581 (9th Cir. 1983). A complaint 7 may be dismissed as a matter of law either for lack of a cognizable legal theory or for 8 insufficient facts under a cognizable theory. Balisteri v. Pacifica Police Dep’t., 901 F.2d 9 696, 699 (9th Cir. 1990).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
Fogerty v. Fantasy, Inc.
510 U.S. 517 (Supreme Court, 1994)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Whittlestone, Inc. v. Handi-Craft Co.
618 F.3d 970 (Ninth Circuit, 2010)
Fantasy, Inc. v. Fogerty
984 F.2d 1524 (Ninth Circuit, 1993)
Michael Lacey v. Joseph Arpaio
693 F.3d 896 (Ninth Circuit, 2012)
Stevenson v. Superior Court
941 P.2d 1157 (California Supreme Court, 1997)
Green v. Ralee Engineering Co.
960 P.2d 1046 (California Supreme Court, 1998)
Tameny v. Atlantic Richfield Co.
610 P.2d 1330 (California Supreme Court, 1980)
Alvarez v. Hill
518 F.3d 1152 (Ninth Circuit, 2008)
In Re TFT-LCD (Flat Panel) Antitrust Litigation
586 F. Supp. 2d 1109 (N.D. California, 2008)
Lee v. BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASS'N
27 Cal. App. 4th 197 (California Court of Appeal, 1994)
Clark v. Allstate Insurance
106 F. Supp. 2d 1016 (S.D. California, 2000)
Ferrick v. Santa Clara University
231 Cal. App. 4th 1337 (California Court of Appeal, 2014)
Tamara Moore v. Mars Petcare US, Inc.
966 F.3d 1007 (Ninth Circuit, 2020)
Sprewell v. Golden State Warriors
266 F.3d 979 (Ninth Circuit, 2001)
Rees v. PNC Bank, N.A.
308 F.R.D. 266 (N.D. California, 2015)
Ivy v. Diamond Shamrock Chemicals Co.
901 F.2d 7 (Second Circuit, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
Gopinath v. Somalogic, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/gopinath-v-somalogic-inc-casd-2023.